The treatment of cancer pain

Drugs of Today

Volumn 40, Issue 3, 2004, Pages 235-245

  Slavin, Konstantin V ^a   Tesoro, Eljim P ^a   Mucksavage, Jeffrey J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CELECOXIB; CODEINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; HYDROMORPHONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; MORPHINE; MORPHINE SULFATE; NABUMETONE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAMORP SR; OXAPROZIN; OXYCODONE; PARACETAMOL; PIROXICAM; ROFECOXIB; SULINDAC; TOLMETIN; UNINDEXED DRUG; VALDECOXIB;

ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CANCER PAIN; COGNITIVE DEFECT; CONSTIPATION; CORDOTOMY; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PRACTICE GUIDELINE; REVIEW; RHIZOTOMY; SEDATION; SIDE EFFECT; THALAMOTOMY; THROMBOCYTE DYSFUNCTION; URINE RETENTION; VOMITING; XEROSTOMIA;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; PAIN; PRACTICE GUIDELINES; WORLD HEALTH ORGANIZATION;

EID: 2342516050     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.3.820087     Document Type: Review

References (28)

1. Centers for Disease Control and Prevention. Leading causes of death reports. CDC Report Website (http://webapp.cdc.gov/sasweb/ncipc/ leadcaus.html), accessed on 4/15/2003.
2. Cancer facts and figures 2002. American Cancer Society 2002, 41.
3. Valdimarsdottir, U., Helgason, A.R., Furst, C.J., Adolfsson, J., Steineck, G. The unrecognized cost of cancer patients' unrelieved symptoms: A nationwide follow-up of their surviving partners. Br J Cancer 2002, 86: 1540-5.
4. Cherny, N.J. The management of cancer pain. CA Cancer J Clin 2000, 50: 70-116.
5. National Comprehensive Cancer Network. NCCN Practice Guidelines for Cancer Pain. Oncology 2000, 14: 135-50.
6. Turk, D.C., Monarch, E.S., Williams, A.D. Cancer patients in pain: Considerations for assessing the whole person. Hematol Oncol Clin North Am 2002, 16: 511-25.
7. Wong, D.L., Baker, C.M. Pain in children: Comparison of assessment scales. Pediatr Nurs 1988, 14: 9-17.
8. Dunn, M.J. Nonsteroidal anti-inflammatory drugs and renal function. Ann Rev Med 1984, 35: 411-28.
9. Morales, E., Mucksavage, J.J. Cyclooxygenase-2 inhibitor-associated acute renal failure: Case report with rofecoxib and review of the literature. Pharmacotherapy 2002, 22: 1317-21.
10. Ruoff, G., Lema, M. Strategies in pain management: New and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 2003, 25S: S21-S31.
11. Grond, S., Radbruch, L., Meuser, T., Loick, G., Sabatowski, R., Lehmann, K.A. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999, 18: 174-9.
12. Coluzzi, P.H., Schwartzberg, L., Conroy, J.D. Jr., et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001, 91: 123-30.
13. Heiskanen, T.E., Ruismaki, P.M., Seppala, T.A., Kalso, E.A. Morphine or oxycodone in cancer pain? Acta Oncologica 2000, 39: 941-7.
14. Kannan, T.R., Saxena, A., Bhatnagar, S., Barry, A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002, 23: 60-5.
15. Mercadante, S., Arcuri, E., Tirelli, W., Casuccio, A. Analgesic effects of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000, 20: 246-52.
16. Jensen, T.S. Anticonvulsants in neuropathic pain: Rationale and clinical evidence. Eur J Pain 2002, 6A: 61-8.
17. Serafini, A.N. Therapy of metastatic bone pain. J Nucl Med 2001, 42: 895-906.
18. Becker, R., Jakob, D., Uhle, E.I., Riegel, T., Bertalanffy, H. The significance of intrathecal opioid therapy for the treatment of neuropathic cancerpain conditions. Stereotact Funct Neurosurg 2000, 75: 16-26.
19. Jones, B., Finlay, I., Ray, A., Simpson, B. Is there still a role for open cordotomy in cancer pain management? J Pain Symptom Manage 2003, 25: 179-84.
20. Nauta, H.J., Soukup, V.M., Fabian, R.H. et al. Punctate midline myelotomy for the relief of visceral cancer pain. J Neurosurg 2000, 92 (Suppl. 2): 125-30.
21. Whittle, I.R., Jenkinson, J.L. CT-guided stereotactic antero-medial pulvinotomy and centromedian-parafascicular thalamotomy for intractable malignant pain. Br J Neurosurg 1995, 9: 195-200.
22. Wong, E.T., Gunes, S., Gaughan, E. et al. Palliation of intractable cancer pain by MRI-guided cingulotomy. Clin J Pain 1997, 13: 260-3.
23. Kanpolat, Y., Caglar, S., Akyar, S., Temiz, C. CT-guided pain procedures for intractable pain in malignancy. Acta Neurochir Suppl (Wien) 1995, 64: 88-91.
24. Taub, E. Spinal cord stimulation for cancer-related pain: A neglected indication? Quadrennial Meeting Am Soc Stereotactic Funct Neurosurg (May 18-21, New York) 2003, 52.
25. Slavin, K.V., Hsu, F.P.K., Fessler, R.G. Intrathecal opioids: intrathecal drug-delivery systems. In: Surgical Management of Pain. K.J. Burchiel (Ed.). Thieme, New York 2002, 603-13.
26. Slavin, K.V., Solko, A.M. Intrathecal narcotics: Spinal and intraventricular. In: Handbook of Stereotactic and Functional Neurosurgery. M. Schulder (Ed.). Marcel Dekker, New York 2003, 443-57.
27. Smith, T.J., Staats, P.S., Deer, T. et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002, 20: 4040-9.
28. Slavin, K., Laurito, C. Surgical approaches to cancer pain: experience of single institution. J Pain 2003, 4 (Suppl 1): 90.